Gujarat Kidney And Super Speciality (GKSL) — Financial Results

Investor Takeaways

Revenue increased by 100% to [amount not verified] compared to [amount not verified] in the same quarter last year

Net profit increased by 100% to [amount not verified] compared to [amount not verified] in the same quarter last year

⚠️ No specific risks identified in this filing

Overall Tone: Neutral based on the numbers only.

Key Financial Highlights

Metric	Value	YoY Change
Revenue	[amount not verified]	100%
Net Profit	[amount not verified]	100%
EBITDA	Not available	Not available
EPS	Not available	Not available
OPM	Not available	Not available

What Changed

The filing reports unaudited standalone and consolidated financial results for Q1 FY2026 (quarter ended June 30, 2026), showing a doubling of both revenue and net profit compared to the same quarter of the previous fiscal year. The company disclosed that its auditor, Y. M. Shah & Co., conducted a limited review under Ind AS 34 and found no material misstatements or missing disclosures. However, the limited assurance provided means the audit scope was restricted and did not cover all aspects of the financial statements as would be required in a full audit. The company filed these results in compliance with SEBI Regulation 33. No additional operational or strategic commentary was included in the filing. The financial performance indicates growth in top-line and bottom-line metrics year-on-year, but the lack of full audit verification introduces a moderate level of verification risk for investors relying on the data.

Peer Comparison

Company	P/E	ROE	ROCE	Market Cap (₹ Cr)
Gujarat Kidney And Super Speciality Limited (GKSL)	Not available	Not available	Not available	1,081.89
Sun Pharmaceutical Industries Limited (SUNPHARMA)	41.28	15.11%	20.34%	4,50,643.09
Divi's Laboratories Limited (DIVISLAB)	72.41	16.56%	22.09%	1,79,470.03
Torrent Pharmaceuticals Limited (TORNTPHARM)	80.06	N/A%	N/A%	1,49,108.91

GKSL's financial metrics such as P/E, ROE, and ROCE are not available in the provided data, while its peers show varying profitability and efficiency ratios with significantly higher market capitalizations.

Risks & Concerns

No specific risks identified in this filing

Quarterly Trend

Not available

📄 View Original Announcement (PDF)

📊 Stock Analysis — GKSL ✨ Ask AI About This

About Gujarat Kidney And Super Speciality Limited (GKSL)

Healthcare · Healthcare · Listed on NSE

Market Cap: ₹1,280.41 Cr P/E: 66.0 ROE: 64.5% ROCE: 77.4%

View full GKSL stock details →

📡 Get AI alerts when GKSL files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track GKSL — Free

💡 Ask AI about this filing

"What were the standalone revenue and profit figures for Q1 FY2026?" "How do consolidated results compare to Q1 FY2025?" "When will the next audited financial results be released?"

Ask AI Free →

📊 More GKSL filings

See all GKSL filings →

🔥 Also filed on 14 August 2026

CEIGALL Ceigall India Limited Financial Results MAHAPEXLTD Maha Rashtra Apex Corporation Limited Corporate Action SAATVIKGL Saatvik Green Energy Limited Financial Results LIBAS Libas Consumer Products Limited Corporate Action GENUSPOWER Genus Power Infrastructures Limited Financial Results LUXIND Lux Industries Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when GKSL files new disclosures

Track GKSL filings, board meetings, and corporate actions. Free email alerts at 5 PM.